Potentially active compounds that improve PAD through angiogenesis: A review

Abstract

Peripheral arterial disease (PAD) has been historically neglected, which has resulted in a lack of effective drugs in clinical practice. However, with the increasing prevalence of diseases like atherosclerosis and diabetes, the incidence of PAD is rising and cannot be ignored. Researchers are exploring the potential of promoting angiogenesis through exogenous compounds to improve PAD. This paper focuses on the therapeutic effect of natural products (Salidroside, Astragaloside IV, etc.) and synthetic compounds (Cilostazol, Dapagliflozin, etc.). Specifically, it examines how they can promote autocrine secretion of vascular endothelial cells, enhance cell paracrine interactions, and regulate endothelial progenitor cell function. The activation of these effects may be closely related to PI3K, AMPK, and other pathways. Overall, these exogenous compounds have promising therapeutic potential for PAD. This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.

Keywords: 20(S)-protopanaxadiol (PubChem CID:11213350); Angiogenesis; Apabetalone (PubChem CID:135564749); Astragaloside IV (PubChem CID:13943297); Aucubin (PubChem CID:91458); Bavachalcone (PubChem CID:6450879) Sitagliptin (PubChem CID:4369359); Caffeine (PubChem CID:2519); Cilostazol (PubChem CID:2754); Curcumin (PubChem CID:969516); Dapagliflozin (PubChem CID:9887712); Diabetes; Empagliflozin (PubChem CID:11949646); Ginsenoside Rg5 (PubChem CID:11550001); Hindlimb ischemia; Liraglutide (PubChem CID:16134956); Naringin (PubChem CID:442428); Natural products; Oroxylin A (PubChem CID:5320315); PAD; Quercetin (PubChem CID:5280343); Resveratrol (PubChem CID:445154); Rivaroxaban(PubChem CID:9875401); Salidroside (PubChem CID:159278); Synthetic compounds.